1. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
   Chung-Han Lee et al, 2021, The Lancet Oncology CrossRef